These discoveries untangle the central role of Hes1 in lung cancer drug resistance: by maintaining CSC stemness, regulating epigenetic remodeling, and forming interactive dialogues with other oncogenic pathways (such as MYCN and STAT3), Hes1 contributes to the construction of multi-layered drug resistance barriers. Here, STAT3 is linked to lung carcinoma.